How specialty pharma and biotech companies can build market access strategies that work in an era of increasing payer scrutiny.
The payer landscape for pharmaceutical launches has undergone structural change. Value-based frameworks, real-world evidence requirements and accelerated NICE timelines have redefined what market access excellence looks like. This report draws on practitioner experience across twelve UK and European launches to identify the factors that determine commercial success.
Senior leaders and practitioners in Pharma & Life Sciences organisations who are responsible for strategy, transformation or technology investment decisions. Written by practitioners who have delivered in this sector — not analysts who have studied it.
How NICE, NHS England and integrated care systems are reshaping access decisions — and what this means for the commercial models, evidence packages and launch timelines that were designed for a different era. The five shifts every market access team needs to understand.
The real-world evidence strategy that supports access in an outcomes-focused environment. How to design the evidence architecture from Phase III onwards — not as a regulatory afterthought but as a commercial foundation.
Key account management in a system-selling environment is fundamentally different from traditional pharma sales. How leading companies are rebuilding their field force capability for ICS engagement, formulary committees and pathway influence.
The internal transformation required to launch effectively in the new environment is as significant as the external commercial challenge. How to align medical, market access, commercial and supply chain around a single launch model — and the people dynamics that determine whether the alignment holds.
Access at launch is the beginning, not the end. How to build the post-launch evidence generation, KAM engagement and payer relationship management that sustains access through the product lifecycle.
Available to senior practitioners and decision-makers in Pharma & Life Sciences. Complete the form below and we will send the full report directly.
We will not share your details. Unsubscribe at any time.